Pathophysiologic Insights from Biomarker Studies in Neurological Disorders
Neuroimmunological and neurodegenerative disorders are major healthcare issues associated with high individual and socioeconomic burden. For many neurological disorders an early diagnosis is key for efficient management and therapy. However, neural tissues from brain, spinal cord or peripheral nerve...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2020 |
Language: | English |
Physical Description: | 1 electronic resource (340 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545141204498 |
---|---|
ctrlnum |
(CKB)5400000000041416 (oapen)https://directory.doabooks.org/handle/20.500.12854/73785 (EXLCZ)995400000000041416 |
collection |
bib_alma |
record_format |
marc |
spelling |
Ruck, Tobias edt Pathophysiologic Insights from Biomarker Studies in Neurological Disorders Frontiers Media SA 2020 1 electronic resource (340 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Neuroimmunological and neurodegenerative disorders are major healthcare issues associated with high individual and socioeconomic burden. For many neurological disorders an early diagnosis is key for efficient management and therapy. However, neural tissues from brain, spinal cord or peripheral nerves are difficult to obtain, and their extraction is often associated with functional deficits. Therefore, in most cases a combination of biomarkers such as radiologic or biochemical findings are used to define a diagnosis in the clinical practice. The development of pathologically-sensitive and easy-to-measure disease biomarkers is a key factor for investigating new medications in phase 2 trials aiming to quickly screen their efficacy, and in phase 3 trials where they are coupled to clinical measures. Moreover, biomarkers are used to predict treatment efficacy and adverse event risk, paving the way for personalized medicine with individual risk assessment and prevention strategies. In the last few decades the enormous technological progress, especially omics technologies, expanded the definition of biomarkers from biochemical and clinical by genetic, proteomic, metabolic or microbial markers. Interestingly, some of the biomarker studies additionally provided important insights into the pathophysiology of neurological disorders. In multiple sclerosis TNF-blocking drugs can promote onset or exacerbation of MS and GWAS (genome-wide association studies) data informed about the underlying mechanisms instructing clinical practice. In Parkinson’s disease (PD), evaluation of Lewy pathology provided new pathophysiological insights attributing PD pathology progression to a prion-like process starting in the gastrointestinal tract. However, many other suggested biomarkers remain solely correlative, often lacking a causative link to the underlying disease mechanisms possibly explaining their lack in sensitivity and specificity. English Medicine bicssc Neurology & clinical neurophysiology bicssc biomarker pathophysiology neuroimmunology neurodegeneration pathomechanism 2-88963-643-7 Moccia, Marcello edt Warnecke, Tobias edt Bittner, Stefan edt Ruck, Tobias oth Moccia, Marcello oth Warnecke, Tobias oth Bittner, Stefan oth |
language |
English |
format |
eBook |
author2 |
Moccia, Marcello Warnecke, Tobias Bittner, Stefan Ruck, Tobias Moccia, Marcello Warnecke, Tobias Bittner, Stefan |
author_facet |
Moccia, Marcello Warnecke, Tobias Bittner, Stefan Ruck, Tobias Moccia, Marcello Warnecke, Tobias Bittner, Stefan |
author2_variant |
t r tr m m mm t w tw s b sb |
author2_role |
HerausgeberIn HerausgeberIn HerausgeberIn Sonstige Sonstige Sonstige Sonstige |
title |
Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
spellingShingle |
Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
title_full |
Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
title_fullStr |
Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
title_full_unstemmed |
Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
title_auth |
Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
title_new |
Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
title_sort |
pathophysiologic insights from biomarker studies in neurological disorders |
publisher |
Frontiers Media SA |
publishDate |
2020 |
physical |
1 electronic resource (340 p.) |
isbn |
2-88963-643-7 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT rucktobias pathophysiologicinsightsfrombiomarkerstudiesinneurologicaldisorders AT mocciamarcello pathophysiologicinsightsfrombiomarkerstudiesinneurologicaldisorders AT warnecketobias pathophysiologicinsightsfrombiomarkerstudiesinneurologicaldisorders AT bittnerstefan pathophysiologicinsightsfrombiomarkerstudiesinneurologicaldisorders |
status_str |
n |
ids_txt_mv |
(CKB)5400000000041416 (oapen)https://directory.doabooks.org/handle/20.500.12854/73785 (EXLCZ)995400000000041416 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField noLinkedField noLinkedField noLinkedField noLinkedField |
_version_ |
1796649061515788288 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03222nam-a2200421z--4500</leader><controlfield tag="001">993545141204498</controlfield><controlfield tag="005">20231214133542.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202111s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041416</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/73785</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041416</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ruck, Tobias</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pathophysiologic Insights from Biomarker Studies in Neurological Disorders</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (340 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neuroimmunological and neurodegenerative disorders are major healthcare issues associated with high individual and socioeconomic burden. For many neurological disorders an early diagnosis is key for efficient management and therapy. However, neural tissues from brain, spinal cord or peripheral nerves are difficult to obtain, and their extraction is often associated with functional deficits. Therefore, in most cases a combination of biomarkers such as radiologic or biochemical findings are used to define a diagnosis in the clinical practice. The development of pathologically-sensitive and easy-to-measure disease biomarkers is a key factor for investigating new medications in phase 2 trials aiming to quickly screen their efficacy, and in phase 3 trials where they are coupled to clinical measures. Moreover, biomarkers are used to predict treatment efficacy and adverse event risk, paving the way for personalized medicine with individual risk assessment and prevention strategies. In the last few decades the enormous technological progress, especially omics technologies, expanded the definition of biomarkers from biochemical and clinical by genetic, proteomic, metabolic or microbial markers. Interestingly, some of the biomarker studies additionally provided important insights into the pathophysiology of neurological disorders. In multiple sclerosis TNF-blocking drugs can promote onset or exacerbation of MS and GWAS (genome-wide association studies) data informed about the underlying mechanisms instructing clinical practice. In Parkinson’s disease (PD), evaluation of Lewy pathology provided new pathophysiological insights attributing PD pathology progression to a prion-like process starting in the gastrointestinal tract. However, many other suggested biomarkers remain solely correlative, often lacking a causative link to the underlying disease mechanisms possibly explaining their lack in sensitivity and specificity.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neurology & clinical neurophysiology</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pathophysiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neuroimmunology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurodegeneration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pathomechanism</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88963-643-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moccia, Marcello</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Warnecke, Tobias</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bittner, Stefan</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruck, Tobias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moccia, Marcello</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Warnecke, Tobias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bittner, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:57:28 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337914910004498&Force_direct=true</subfield><subfield code="Z">5337914910004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337914910004498</subfield></datafield></record></collection> |